Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp.
Diabetes research and clinical practice
confidence
Key findings
Hyperglycemia significantly reduced GH response (peak and AUC) to combined GHRH+GHRP-6 in normal-weight type 2 diabetics.
View source on PubMed (PMID 14693411) ↗
- Sample size
- 12
- Population
- Male patients with type 2 diabetes (mean age 53.9 yrs, BMI 25.58, HbA1c 8.7%)
- Dosing
- GHRH 100 mcg + GHRP-6 100 mcg i.v. bolus
- Duration
- Acute (euglycemic and hyperglycemic clamp sessions)
- Route
- intravenous
- Blinding
- not_reported
- Controls
- none
- Drug class
- GH secretagogue
Measured endpoints
- Basal GH levels (hyperglycemic vs euglycemic clamp)No changehormonalnot_significanteffect: 2.9±0.99 mU/l vs 1.48±0.44 mU/l
- Peak GH response to GHRH+GHRP-6Decreasedhormonalsignificanteffect: 112.45±14.45 mU/l vs 151.06±16.87 mU/l
- Area under the GH curveDecreasedhormonalsignificanteffect: 6974.49±1001.95 vs 9560.75±1140.65 mU/l/min
Full abstract
The aim of this study was to investigate the effect of two different glucose levels on GH response to the combined administration of GHRH+GHRP-6 in patients with type 2 diabetes. GH response to i.v. bolus of GHRH+GHRP-6 (100 mcg, each) was measured in 12 male patients with type 2 diabetes (mean age: 53.9+/-1.59 years; BMI: 25.58+/-0.39 kg/m(2); mean HbA(1c): 8.7+/-0.42%), during a euglycemic (mean glucose: 4.92+/-0.08 mmol) hyperinsulinemic clamp (insulin infusion rate of 100 mU/kg/h) and a hyperglycemic clamp (mean glucose: 12.19+/-0.11 mmol/l). There was no difference in basal GH levels between the hyperglycemic and euglycemic clamps (2.9+/-0.99 mU/l versus 1.48+/-0.44 mU/l; P>0.05). Peak GH response to GHRH+GHRP-6 during the hyperglycemic clamp was lower than in the englycemic clamp (112.45+/-14.45 mU/l versus 151.06+/-16.87 mU/l; P<0.05). Area under the GH curve was lower in the hyperglycemic than in the euglycemic clamp (6974.49+/-1001.95 mU/l/min versus 9560.75+/-1140.65 mU/l/min; P<0.05). It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.